Annual report [Section 13 and 15(d), not S-K Item 405]

Simple Retirement Account for Employees (the "Simple IRA")

v3.26.1
Simple Retirement Account for Employees (the "Simple IRA")
 12 Months Ended
Dec. 31, 2025
Retirement Benefits [Abstract]  
Simple Retirement Account for Employees (the "Simple IRA")

16. Simple Retirement Account for Employees (“Simple IRA”) and 401(k) Plan

The Company established an individual retirement plan for employees effective January 1, 2013 under Section 408(p) of the Internal Revenue Code. The Simple IRA covers substantially all employees of the Company who received at least $5,000 in compensation from the Company during any two preceding years and are reasonably expected to receive at least $5,000 in compensation from the Company in the current year of participation. Subject to certain overall statutory limitations, the Company must match employee contributions up to 3% of employees’ qualified compensation for the year. On July 1, 2025, the Company terminated the Simple IRA and implemented the Inhibikase Therapeutics 401(k) Plan (the “401(k) Plan”). The 401(k) Plan covers all employees of the Company, and all employees are eligible for the 401(k) match which is up to 3.5% of an employee's eligible salary.

Company contributions under the Simple IRA were $54,390 and $59,905 for the years ended December 31, 2025 and 2024, respectively. Company contributions under the 401(k) Plan were $104,082 for the year ended December 31, 2025.